Eisai Presents New Data Highlighting Long-Term Efficacy of LEQEMBI for Early Alzheimer’s Disease Treatment ###

###
1. Three Years of Continuous Treatment: New clinical data presented at the Alzheimer's Association International Conference (AAIC) 2024 demonstrates that LEQEMBI (lecanemab-irmb) continues to show significant cognitive benefits for early Alzheimer's disease patients over three years of treatment, reducing clinical decline by -0.95 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale.
2. Dual-Acting Mechanism: LEQEMBI is the only early AD treatment that supports neuronal function by clearing highly toxic protofibrils, which continue to cause neuronal injury and death even after plaques have been cleared from the brain.
3. Clarity AD Study: The global Phase 3 study involved 1,795 patients and showed that 95% of patients who completed the core study chose to continue in the open-label extension study, indicating a high level of patient satisfaction and continued benefit.
4. FDA Approval: LEQEMBI received full FDA approval based on Phase 3 data from the Clarity AD clinical trial, which met its primary endpoint and all key secondary endpoints with statistically significant results.
5. Revenue Projections: Eisai has set a new revenue target of 56.5 billion yen (approximately $361 million) for LEQEMBI during the 2024 fiscal year, which analysts believe is more realistic and achievable than previous projections.
6. Subcutaneous Formulation: Eisai and Biogen are developing a more convenient subcutaneous formulation of LEQEMBI, which they have begun submitting for FDA approval. This could further boost sales and uptake due to its increased convenience.